Wall Street analysts expect that Wave Life Sciences Ltd (NASDAQ:WVE) will post $7.82 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Wave Life Sciences’ earnings. The highest sales estimate is $12.50 million and the lowest is $3.02 million. Wave Life Sciences reported sales of $3.62 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 116%. The company is expected to issue its next earnings results on Friday, March 6th.
On average, analysts expect that Wave Life Sciences will report full year sales of $22.36 million for the current financial year, with estimates ranging from $16.60 million to $26.10 million. For the next year, analysts anticipate that the business will report sales of $77.78 million, with estimates ranging from $13.88 million to $150.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Wave Life Sciences.
Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.34) by ($0.14). Wave Life Sciences had a negative return on equity of 128.21% and a negative net margin of 1,015.84%. The business had revenue of $2.93 million during the quarter, compared to analysts’ expectations of $6.30 million.
In other Wave Life Sciences news, VP Chandra Vargeese sold 6,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $32.34, for a total value of $194,040.00. Also, Director Gregory L. Verdine sold 30,039 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $30.63, for a total value of $920,094.57. Following the completion of the transaction, the director now owns 36,009 shares of the company’s stock, valued at approximately $1,102,955.67. The disclosure for this sale can be found here. 39.70% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in WVE. Janus Henderson Group PLC increased its holdings in Wave Life Sciences by 16.1% during the 2nd quarter. Janus Henderson Group PLC now owns 3,392,298 shares of the company’s stock valued at $88,505,000 after acquiring an additional 470,402 shares in the last quarter. Redmile Group LLC grew its position in shares of Wave Life Sciences by 16.8% in the third quarter. Redmile Group LLC now owns 3,177,760 shares of the company’s stock valued at $65,239,000 after purchasing an additional 458,053 shares during the last quarter. BlackRock Inc. increased its stake in shares of Wave Life Sciences by 6.7% during the 2nd quarter. BlackRock Inc. now owns 1,811,996 shares of the company’s stock worth $47,275,000 after purchasing an additional 113,292 shares in the last quarter. Northern Trust Corp increased its stake in shares of Wave Life Sciences by 2.0% during the 2nd quarter. Northern Trust Corp now owns 265,291 shares of the company’s stock worth $6,922,000 after purchasing an additional 5,145 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Wave Life Sciences by 8.7% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 115,769 shares of the company’s stock worth $3,021,000 after purchasing an additional 9,273 shares during the last quarter. Institutional investors and hedge funds own 90.00% of the company’s stock.
Shares of NASDAQ WVE traded down $0.14 during trading on Monday, hitting $32.34. 162,264 shares of the company were exchanged, compared to its average volume of 327,353. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.88 and a quick ratio of 1.88. Wave Life Sciences has a 1 year low of $17.59 and a 1 year high of $50.98. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -6.39 and a beta of 0.91. The firm’s fifty day moving average price is $27.74 and its 200 day moving average price is $24.26.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Read More: Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.